SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:du-23296"
 

Sökning: onr:"swepub:oai:DiVA.org:du-23296" > Population pharmaco...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003824naa a2200469 4500
001oai:DiVA.org:du-23296
003SwePub
008161028s2016 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:du-232962 URI
0247 a https://doi.org/10.1093/infdis/jiw3382 DOI
040 a (SwePub)du
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Tchaparian, E.4 aut
2451 0a Population pharmacokinetics and pharmacodynamics of lumefantrine in young Ugandan children treated with artemether-lumefantrine for uncomplicated malaria
264 c 2016-07-28
264 1b Oxford University Press (OUP),c 2016
338 a electronic2 rdacarrier
520 a Background. The pharmacokinetics and pharmacodynamics of lumefantrine, a component of the most widely used treatment for malaria, artemether-lumefantrine, has not been adequately characterized in young children. Methods. Capillary whole-blood lumefantrine concentration and treatment outcomes were determined in 105 Ugandan children, ages 6 months to 2 years, who were treated for 249 episodes of Plasmodium falciparum malaria with artemether-lumefantrine. Results. Population pharmacokinetics for lumefantrine used a 2-compartment open model with first-order absorption. Age had a significant positive correlation with bioavailability in a model that included allometric scaling. Children not receiving trimethoprim-sulfamethoxazole with capillary whole blood concentrations <200 ng/mL had a 3-fold higher hazard of 28-day recurrent parasitemia, compared with those with concentrations >200 ng/mL (P =. 0007). However, for children receiving trimethoprim-sulfamethoxazole, the risk of recurrent parasitemia did not differ significantly on the basis of this threshold. Day 3 concentrations were a stronger predictor of 28-day recurrence than day 7 concentrations. Conclusions. We demonstrate that age, in addition to weight, is a determinant of lumefantrine exposure, and in the absence of trimethoprim-sulfamethoxazole, lumefantrine exposure is a determinant of recurrent parasitemia. Exposure levels in children aged 6 months to 2 years was generally lower than levels published for older children and adults. Further refinement of artemether-lumefantrine dosing to improve exposure in infants and very young children may be warranted. © 2016 The Author.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicin0 (SwePub)3022 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicine0 (SwePub)3022 hsv//eng
653 a Malaria; population pharmacokinetics; lumefantrine; artemisinin combination therapy; antimalarial; nonlinear mixed effects modeling; pharmacodynamics; trimethoprim-sulfamethoxazole
653 a Hälsa och välfärd
653 a Health and Welfare
7001 a Sambol, N.C.4 aut
7001 a Arinaitwe, E.4 aut
7001 a McCormack, S.A.4 aut
7001 a Bigira, V.4 aut
7001 a Wanzira, H.4 aut
7001 a Blessborn, Daniel4 aut
7001 a Bergqvist, Yngveu Högskolan Dalarna,Medicinsk vetenskap4 aut0 (Swepub:du)ybq
7001 a Aweeka, F.T.4 aut
7001 a Parikh, S.4 aut
7102 a Högskolan Dalarnab Medicinsk vetenskap4 org
7730 t Journal of Infectious Diseasesd : Oxford University Press (OUP)g 214:8, s. 1243-1251q 214:8<1243-1251x 0022-1899x 1537-6613
8564 u https://doi.org/10.1093/infdis/jiw338y Fulltext
8564 u https://du.diva-portal.org/smash/get/diva2:1040768/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
8564 u https://academic.oup.com/jid/article-pdf/214/8/1243/17412244/jiw338.pdf
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:du-23296
8564 8u https://doi.org/10.1093/infdis/jiw338

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy